Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph P Balthasar

Showing results (21-30 of 88) with videos related to

Pageof 9
Sort By:
Drug Metabolism and Pharmacokinetics|December 8, 2018
Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and developmentPatrick M Glassman, Joseph P Balthasar
The AAPS Journal|April 1, 2016
Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal CancerVeena A Thomas, Joseph P Balthasar
International Journal of Pharmaceutics|April 5, 2016
Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodiesPatrick M Glassman, Joseph P Balthasar
AAPS Pharmsci|March 21, 2003
Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitroEvelyn D Lobo, Joseph P Balthasar
Blood|August 30, 2002
Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopeniaRyan J Hansen, Joseph P Balthasar
Journal of Pharmacokinetics and Pharmacodynamics|July 6, 2016
Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodiesPatrick M Glassman, Joseph P Balthasar
Cancer Biology & Medicine|August 18, 2022
Strategies to enhance monoclonal antibody uptake and distribution in solid tumorsBrandon M Bordeau, Joseph P Balthasar
Journal of Pharmaceutical Sciences|February 1, 2005
Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditionsKate E Getman, Joseph P Balthasar
Mabs|January 19, 2010
Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenograftsShweta R Urva, Joseph P Balthasar
Thrombosis and Haemostasis|January 17, 2003
Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptorRyan J Hansen, Joseph P Balthasar
Pageof 9

Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Drug Metabolism and Pharmacokinetics|December 8, 2018
Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and developmentPatrick M Glassman, Joseph P Balthasar
The AAPS Journal|April 1, 2016
Sorafenib Decreases Tumor Exposure to an Anti-carcinoembryonic Antigen Monoclonal Antibody in a Mouse Model of Colorectal CancerVeena A Thomas, Joseph P Balthasar
International Journal of Pharmaceutics|April 5, 2016
Application of a catenary PBPK model to predict the disposition of "catch and release" anti-PCSK9 antibodiesPatrick M Glassman, Joseph P Balthasar
AAPS Pharmsci|March 21, 2003
Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitroEvelyn D Lobo, Joseph P Balthasar
Blood|August 30, 2002
Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopeniaRyan J Hansen, Joseph P Balthasar
Journal of Pharmacokinetics and Pharmacodynamics|July 6, 2016
Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodiesPatrick M Glassman, Joseph P Balthasar
Cancer Biology & Medicine|August 18, 2022
Strategies to enhance monoclonal antibody uptake and distribution in solid tumorsBrandon M Bordeau, Joseph P Balthasar
Journal of Pharmaceutical Sciences|February 1, 2005
Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditionsKate E Getman, Joseph P Balthasar
Mabs|January 19, 2010
Target mediated disposition of T84.66, a monoclonal anti-CEA antibody: application in the detection of colorectal cancer xenograftsShweta R Urva, Joseph P Balthasar
Thrombosis and Haemostasis|January 17, 2003
Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptorRyan J Hansen, Joseph P Balthasar
Pageof 9